FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775687989> ?p ?o ?g. }

• W2775687989 endingPage "325" @default.
• W2775687989 startingPage "307" @default.
• W2775687989 abstract "IDO1 and TDO2 catalyze the commitment and rate-limiting step of the KYN metabolic pathway that produces the endogenous AhR agonist KYN. Activation of AhR by KYN contributes to the immunosuppressive tumor microenvironment and supports cancer immune escape. Three differential therapeutic modalities, each intercepting a unique node of the IDO1/TDO2–KYN–AhR enzymatic/signaling cascade, have been pursued for the development of novel cancer immunotherapies. Inhibition of IDO1/TDO2 prevents the formation of the endogenous AhR ligand KYN. At least four small-molecule selective IDO1 inhibitors are in clinical development for the treatment of advanced cancers. Systemic depletion of KYN prevents its engagement with AhR. Engineered kynureninase degrades extracellular KYN and shows remarkable efficacy in mouse tumor models. Inhibition of AhR activation by synthetic AhR modulators: an advantage of AhR antagonists is to broadly inhibit the immunosuppressive effect of any endogenous and exogenous AhR ligands. Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) catalyze the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the immunosuppressive effect of IDO1 has been attributed mainly to reduced levels of tryptophan, which activates the kinase general control nonderepressible 2 (GCN2). Emerging data have shed light on an unexpected role of the ligand-activated transcription factor aryl hydrocarbon receptor (AhR) in transducing the tumor immune escape function imparted by IDO1 and TDO2. AhR activation by the IDO1/TDO2 product KYN leads to the generation of immune-tolerant dendritic cells (DCs) and regulatory T cells, which collectively foster a tumor immunological microenvironment that is defective in recognizing and eradicating cancer cells. Multiple IDO1 inhibitors have been evaluated in clinical trials. There are novel modalities downstream of IDO1/TDO2 for pharmacological interventions. We review recent progress and future perspectives in targeting the IDO1/TDO2–KYN–AhR signaling pathway for the development of novel cancer immunotherapies. Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) catalyze the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the immunosuppressive effect of IDO1 has been attributed mainly to reduced levels of tryptophan, which activates the kinase general control nonderepressible 2 (GCN2). Emerging data have shed light on an unexpected role of the ligand-activated transcription factor aryl hydrocarbon receptor (AhR) in transducing the tumor immune escape function imparted by IDO1 and TDO2. AhR activation by the IDO1/TDO2 product KYN leads to the generation of immune-tolerant dendritic cells (DCs) and regulatory T cells, which collectively foster a tumor immunological microenvironment that is defective in recognizing and eradicating cancer cells. Multiple IDO1 inhibitors have been evaluated in clinical trials. There are novel modalities downstream of IDO1/TDO2 for pharmacological interventions. We review recent progress and future perspectives in targeting the IDO1/TDO2–KYN–AhR signaling pathway for the development of novel cancer immunotherapies. a member of the basic helix-loop-helix (bHLH)-Per/ARNT/Sim (bHLH-PAS) family of transcription factors. The PAS B domain contains the ligand-binding site that recognizes structurally diverse organic molecules. the occurrence of severe toxicities in human cancer patients that generally involve grade 3 or higher levels of toxicity. They are determined during Phase I clinical trials of cancer therapy. DLTs define the maximum tolerated dose (MTD) that will be applied in later phases of clinical trials. the processes by which cells of the immune system monitor and recognize foreign pathogens or neoantigens in the body. a type II interferon (IFN) cytokine that plays an important role in the regulation of the immune system and the control of infections. IFN-γ produced by cytotoxic T cells contributes significantly to the eradication of cancer cells via adaptive immune antitumor responses. the MTD in human patients is determined during Phase I clinical trials and is the dose used for efficacy studies for the development of anticancer drugs. an in vitro assay to measure T cell reactivity to external stimuli. a heterogeneous group of immune cells of myeloid origin that are potent suppressors of T cell functions. Their population is increased in tumor tissue to support cancer proliferation and metastasis. a type of immunosuppressive T cells that are crucial to modulating immune cell homeostasis to maintain tolerance to self-antigens and to prevent autoimmune disease. Cancer cells upregulate Tregs to induce T cell anergy and evade immunosurveillance. the occurrences of adverse effect related to the use of a drug for treating a disease. TRAEs can be caused by a drug via on-target or off-target actions. the cellular environment that is composed of the cancer cells, immune cells (lymphocytes, MDSCs, dendritic cells, tumor-associated macrophages), fibroblasts, signaling molecules, blood vessels, and the extracellular matrix. The TME is often also characterized by hypoxia (lack of oxygen) and high acidity (lactate from excessive glycolysis) that limit the efficacy of anticancer agents." @default.
• W2775687989 created "2017-12-22" @default.
• W2775687989 creator A5010628698 @default.
• W2775687989 creator A5038061473 @default.
• W2775687989 date "2018-03-01" @default.
• W2775687989 modified "2023-10-14" @default.
• W2775687989 title "Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities" @default.
• W2775687989 cites W1495607276 @default.
• W2775687989 cites W1545334093 @default.
• W2775687989 cites W1603640418 @default.
• W2775687989 cites W1608778557 @default.
• W2775687989 cites W1611944043 @default.
• W2775687989 cites W1931474344 @default.
• W2775687989 cites W1967124137 @default.
• W2775687989 cites W1967885926 @default.
• W2775687989 cites W1975124499 @default.
• W2775687989 cites W1984678083 @default.
• W2775687989 cites W1985443071 @default.
• W2775687989 cites W1993003564 @default.
• W2775687989 cites W1998142996 @default.
• W2775687989 cites W2004522121 @default.
• W2775687989 cites W2007316487 @default.
• W2775687989 cites W2010378562 @default.
• W2775687989 cites W2011427930 @default.
• W2775687989 cites W2024408959 @default.
• W2775687989 cites W2029458048 @default.
• W2775687989 cites W2038234028 @default.
• W2775687989 cites W2040568539 @default.
• W2775687989 cites W2044104392 @default.
• W2775687989 cites W2044651251 @default.
• W2775687989 cites W2052006922 @default.
• W2775687989 cites W2056036930 @default.
• W2775687989 cites W2066352983 @default.
• W2775687989 cites W2068912461 @default.
• W2775687989 cites W2072078248 @default.
• W2775687989 cites W2076927594 @default.
• W2775687989 cites W2079783858 @default.
• W2775687989 cites W2087435147 @default.
• W2775687989 cites W2087801719 @default.
• W2775687989 cites W2088492376 @default.
• W2775687989 cites W2097049582 @default.
• W2775687989 cites W2097156202 @default.
• W2775687989 cites W2097615954 @default.
• W2775687989 cites W2098921988 @default.
• W2775687989 cites W2103553504 @default.
• W2775687989 cites W2106041642 @default.
• W2775687989 cites W2107312924 @default.
• W2775687989 cites W2111225227 @default.
• W2775687989 cites W2112891363 @default.
• W2775687989 cites W2113906692 @default.
• W2775687989 cites W2126932404 @default.
• W2775687989 cites W2129383700 @default.
• W2775687989 cites W2136731993 @default.
• W2775687989 cites W2139027624 @default.
• W2775687989 cites W2141474125 @default.
• W2775687989 cites W2146339140 @default.
• W2775687989 cites W2148196931 @default.
• W2775687989 cites W2149398709 @default.
• W2775687989 cites W2149791488 @default.
• W2775687989 cites W2151197941 @default.
• W2775687989 cites W2152524078 @default.
• W2775687989 cites W2156195812 @default.
• W2775687989 cites W2159543644 @default.
• W2775687989 cites W2161713280 @default.
• W2775687989 cites W2169184645 @default.
• W2775687989 cites W2169417565 @default.
• W2775687989 cites W2184759047 @default.
• W2775687989 cites W2189304488 @default.
• W2775687989 cites W2195930032 @default.
• W2775687989 cites W2197798862 @default.
• W2775687989 cites W2202809648 @default.
• W2775687989 cites W2220882815 @default.
• W2775687989 cites W2262222944 @default.
• W2775687989 cites W2266683146 @default.
• W2775687989 cites W2275249553 @default.
• W2775687989 cites W2308639964 @default.
• W2775687989 cites W2333895855 @default.
• W2775687989 cites W2340366736 @default.
• W2775687989 cites W2341631860 @default.
• W2775687989 cites W2359306646 @default.
• W2775687989 cites W2467541392 @default.
• W2775687989 cites W2532166186 @default.
• W2775687989 cites W2553568639 @default.
• W2775687989 cites W2554808068 @default.
• W2775687989 cites W2561926137 @default.
• W2775687989 cites W2570766240 @default.
• W2775687989 cites W2583716329 @default.
• W2775687989 cites W2587048937 @default.
• W2775687989 cites W2587691649 @default.
• W2775687989 cites W2594368015 @default.
• W2775687989 cites W2594615455 @default.
• W2775687989 cites W2602843166 @default.
• W2775687989 cites W2603408994 @default.
• W2775687989 cites W2605965273 @default.
• W2775687989 cites W2616467994 @default.
• W2775687989 cites W2623028642 @default.
• W2775687989 cites W2623782848 @default.
• W2775687989 cites W2724690266 @default.

• next